Modified Blumgart anastomosis without pancreatic duct-to-jejunum mucosa anastomosis for pancreatoduodenectomy: a feasible and safe novel technique ================================================================================================================================================== * Xiaoqing Wang * Yang Bai * Mangmang Cui * Qingxiang Zhang * Wei Zhang * Feng Fang * Tianqiang Song ## Abstract **Objective:** This study proposed a modified Blumgart anastomosis (m-BA) that uses a firm ligation of the main pancreatic duct with a supporting tube to replace the pancreatic duct-to-jejunum mucosa anastomosis, with the aim of simplifying the complicated steps of the conventional BA (c-BA). Thus, we observe if a difference in the risk of postoperative pancreatic fistula (POPF) exists between the two methods. **Methods:** The m-BA anastomosis method has been used since 2010. From October 2011 to October 2015, 147 patients who underwent pancreatoduodenectomy (PD) using BA in Tianjin Medical University Cancer Institute and Hospital were enrolled in this study. According to the type of pancreatojejunostomy (PJ), 50 patients underwent m-BA and 97 received c-BA. The two patient cohorts were compared prospectively to some extent but not randomized, and the evaluated variables were operation time, the incidence rate of POPF, and other perioperative complications. **Results:** The operation time showed no significant difference (*P* > 0.05) between the two groups, but the time of duct-to-mucosa anastomosis in the m-BA group was much shorter than that in the c-BA group ( *P* < 0.001). The incidence rate of clinically relevant POPF was 12.0% (6/50) in the modified group and 10.3% (10/97) in the conventional group ( *P* > 0.05), which means that the modified anastomosis method did not cause additional pancreatic leakage. The mean length of postoperative hospital stay of the m-BA group was 23 days, and that of the c-BA group was 22 days ( *P* > 0.05). **Conclusions:** Compared with the conventional BA, we suggest that the modified BA is a feasible, safe, and effective operation method for P J of PD with no sacrifice of surgical quality. In the multivariate analysis, we also found that body mass index (≥ 25 kg/m2) increased the risk of POPF. * Pancreatoduodenectomy * pancreatojejunostomy * modified Blumgart anastomosis * postoperative complications * postoperative pancreatic fistula ## Introduction Pancreatoduodenectomy (PD) applied as a standard surgical approach for both benign and malignant tumors of the pancreatic head and periampullary carcinoma has benefitted most patients. In the last two decades, the popularization of PD certainly profits from not the improvement of surgical techniques and instruments but the perioperative management significantly reducing the mortality rate after PD. Furthermore, several large medical records have nearly reached a zero mortality rate1, 2. However, many patients must endure the complications after operation, which include pancreatic fistula, delayed gastric emptying, postoperative pancreatic fistula (POPF)-related hemorrhage, intra-abdominal and pleural effusions, wound infection, bacteremia, and septic shock. Although the incidence of postoperative complications showed a downward trend, the desired result is still difficult to achieve3, 4. POPF is considered as the most common and threatening complication, which can cause potential secondary infection, long-term hospitalization, and serious economic burden5. Numerous relevant literatures have reported that the occurrence of POPF is not only related to the patients’ own features such as higher body mass index (BMI), soft texture of the pancreas, small pancreatic duct diameter, and high blood loss6–8, but is also influenced by the anastomosis method in pancreatojejunostomy (PJ)9–11. Thus, the most urgent issue in improving postoperative condition is the development of a safer and more effective anastomotic method. Currently, various anastomotic techniques and differences still exist in PJ. Blumgart anastomosis (BA) using a U-suture technique has attracted great attention and has been proved to be a common and effective technique12–14. On the basis of the limitation of complex operation procedures in the conventional BA (c-BA), many surgical specialists simplified the procedures and achieved satisfactory results5, 15, 16. In our study, to improve the original method, we made a further change by using firm ligation of a supporting tube and the main pancreatic duct to replace the pancreatic duct-to-jejunum mucosa anastomosis of the c-BA. In this study, we attentively present the m-BA in detail. Furthermore, we made a synthetic comparison of the m-BA and c-BA to analyze the advantages of the m-BA in improving the surgical procedure and postoperative complications. ## Patients and methods ### Patient selection Between October 2011 and October 2015, 147 consecutive patients who underwent PD using BA in the Department of Hepatobiliary Surgery at Tianjin Medical University Cancer Institute and Hospital were enrolled in this study. According to the type of PJ, 50 patients underwent the modified BA (m-BA; the modified group) and the remaining 97 patients underwent the conventional BA (c-BA; the conventional group) in this retrospective study. No invasion of the superior mesenteric vessels, and distant and portal vein metastases were found in all the patients. The two patient cohorts were compared, and the evaluated variables were operation time, the incidence rate of POPF, postoperative hospital stay (POHS), and other perioperative complications. Surgical technique All the 147 patients underwent the standard PD performed by experienced chief physicians. The patients in the m-BA group underwent operation by our principal researcher, and in the other group, the operation was performed by two experienced surgeons in our department. The primary lesions were either distal common bile duct or periampullary carcinomas without vascular invasion. The surgical procedure of the c-BA was similar to the classic technique reported previously12–14. Between the modified group or conventional group, no substantial differences in gastrointestinal anastomosis and cholangiojejunostomy were found, except for pancreaticojejunostomy. Two drainage tubes were respectively placed at the underside of the pancreaticojejunostomy and cholangiojejunostomy by routine. ### Modified Blumgart anastomosis (1) Mobilization of the main pancreatic duct (MPD): mutilation of the pancreatic parenchyma was performed with an electrotome. Small bleeding spots and small branches of pancreatic ducts according to its thickness were managed with electrical coagulation or ligated with 5-0 monofilament stitches. The MPD was freed carefully with a clamp technique, and its length was adequately up to 1–1.5 cm. (2) Placement and fixation of the MPD supporting tube: a small opening was cut with ophthalmic forceps on the side wall of the exposed MPD, and then a short anesthetic extension tube was inserted in the MPD in advance from the opening, acting as the internal stent, which used to drain the pancreatic fluid to the intestinal tract through a small opening in the jejunum (**Figure 1A**). To fully fix the internal stent and MPD, a 5-0 polypropylene suture that transverse sutured the pancreatic parenchyma was entwined for 2–4 rounds on the overlapping parts of the internal stent and MPD, and then fastened (**Figure 1B** and **2**). (3) Establishment of U-sutures: five or six double-armed 3-0 polypropylene sutures were pierced through the pancreatic stump from front to back, nearly 1 cm lateral to the previous sutures, and then reverted through the posterior part of the pancreatic stump after the seromuscular layer of the jejunum was bitten (**Figure 1C**). The sutures should be clear of the MPD to avoid unnecessary damage. U-sutures were placed without tightening on the surface of the pancreas and held with rubber shod clamps separately. (4) Tightening of the U-sutures: One needle of the double-armed 3-0 polypropylene sutures was longitudinally sutured through the seromuscular layer of the jejunum (**Figure 1D**). The previous U-sutures were tightened gently and knotted in case of laceration of the pancreas. Here, we used the ventral wall of the jejunum to cover the pancreatic stump (**Figure 1E**). ![1](http://www.cancerbiomed.org/https://www.cancerbiomed.org/content/cbm/15/1/79/F1.medium.gif) [1](http://www.cancerbiomed.org/content/15/1/79/F1) 1 The operation sketch map of the modified Blumgart anastomosis. (A) The MPD was freed adequately up to 1–1.5 cm and then a short anesthetic extension tube was inserted in the MPD through the opening cut in advance. (B) A 5–0 polypropylene suture that transverse sutured the pancreatic parenchyma was entwined 2–4 laps on the overlapping parts of the internal stent and the MPD, then fasten it. (C-E) The establishment of the U-sutures. ![2](http://www.cancerbiomed.org/https://www.cancerbiomed.org/content/cbm/15/1/79/F2.medium.gif) [2](http://www.cancerbiomed.org/content/15/1/79/F2) 2 The operation pictures. (A) The mobilization of the main pancreatic duct (MPD). (B) The supporting tube was inserted in MPD from the side wall opening. (C) To make the internal stent and the MPD fully fixed, a 5–0 polypropylene suture that transverse sutured the pancreatic transaction was entwined 2–4 laps on the overlapping parts of the internal stent and the MPD, then fasten it. ### Postoperative management and assessment of POPF The vital sign and drainage of each tube were carefully monitored postoperatively. Prophylactic antibiotics, including second- or third-generation cephalosporin, was routinely administered, but postoperative administration of octreotide was not conventional. On the first postoperative day, bacterial examination, including aerobic and anaerobic bacterial cultures, of drainage fluid was routinely performed. At 3, 5, and 7 days, the amylase levels were measured. Blood culture, routine blood test, and abdominal ultrasonography were immediately performed if the patient had a fever. POPF was diagnosed and graded in accordance with the International Study Group on Pancreatic Fistula (ISGPF) classification 201617. Biochemical fistula POPF was defined as “measurable fluid output on or after postoperative day 3, with an amylase content higher than 3 times the upper normal serum level, ” which has no impact on the normal postoperative pathway and POHS. Clinically significant POPF are of grades B and C. Grade B POPF requires a change in the management of the expected postoperative pathway. Whenever reoperation is needed or organ failure occurs, the fistula shifts to a grade C POPF. ### Data collection and outcome measures The clinical related data collected and analyzed included age, sex, preoperative serum albumin, BMI, and preoperative biliary drainage. The following factors associated with POPF due to the operation were also recorded attentively: pancreatic texture, diameter of the MPD, pathological diagnosis, operation time, blood loss volume, and perioperative blood transfusion. The main end points were the incidence rate of clinically significant POPF according to the ISGPF definition and the duration of POHS. The secondary end point included some postoperative complications (delayed gastric emptying, POPF-related hemorrhage, intra-abdominal and pleural effusions, wound infection, bacteremia, septic shock, and in-hospital mortality) and readmission within 30 days after discharge. ### Statistical analysis All statistical analyses were performed using SPSS version 23.0 (IBM, USA). Continuous variables were expressed as mean ± SD and compared using the Student's *t*-test. The Chi-square test and Fisher exact test were applied to the categorical variables. The factors associated with POPF were evaluated in the univariate and multivariate analyses by using the Chi-square test and logistic regression analysis, respectively. A *P*-value of <0.05 was considered statistically significant. ## Results ### Patient demographic The patient’s demographic characteristics are shown in **Table 1**. No significant differences in the main variables, namely age, sex ratio, BMI, preoperative serum albumin level, pancreatic texture, pathological diagnosis, operation time, blood loss volume, and perioperative blood transfusion, were found. Our statistical results demonstrate that a MPD of <3 mm accounted for a larger proportion in the m-BA group than in the c-BA group (32.0% *vs* 12.0%, *P* = 0.004). Moreover, most people in the m-BA group received preoperative biliary drainage (17.5% *vs* 44.0%, *P* < 0.001). The duct-to-mucosa anastomosis time in the m-BA group was 11 ± 1 min, which was apparently shorter than that in the c-BA group (32 ± 4 min, *P* < 0.001). Operation time showed no significant difference between the two groups ( *P* > 0.05), which may be due to the time of duct-to-mucosa anastomosis being just a part of the entire operation time. View this table: [1](http://www.cancerbiomed.org/content/15/1/79/T1) 1 Demographic, characteristics and operational indexes of the patients ### Postoperative complications The postoperative complications in the two groups are shown in **Table 2**. POPF occurred in 6 patients in the m-BA group, among whom were 6 (12.0%) and 0 with ISGPF grade B and C POPF. In the c-BA group, 10 patients had a pancreatic fistula, and 10 (10.3%) and 0 had ISGPF grade B and C POPF, respectively. No significant difference in the incidence of clinically relevant POPF was found between the two groups (*P* > 0.05). In addition, the incidence rates of other postoperative complications, including delayed gastric emptying, POPF-related hemorrhage, intra-abdominal and pleural effusions, wound infection, bacteremia, and septic shock, were essentially similar between the two groups ( *P* > 0.05). No in-hospital death occurred in the m-BA group, while one patient died of infection caused by POPF in the c-BA group. The POHS durations in the m-BA and c-BA groups were 23 ± 8 and 22 ± 10 days, respectively, showing no significant difference ( *P* > 0.05). View this table: [2](http://www.cancerbiomed.org/content/15/1/79/T2) 2 Pancreatic fistula and perioperative complications of pancreatoduodenectomy patients ### Risk factors for POPF The risk factors for POPF are shown in **Table 3**. The univariate analysis revealed that BMI (≥25 kg/m2; *P* = 0.009) and MPD diameter (<3 mm;*P* = 0.019) were associated with POPF. However, the multivariate analysis revealed that only BMI (≥25 kg/m2; *P* = 0.046) was an independent risk factor for clinically significant POPF. We particularly wanted to confirm that the anastomosis methods were not related to the occurrence of pancreatic leakage (*P* > 0.05). However, as described earlier, the time in the m-BA group was much shorter than that in the c-BA group, with a significant difference ( *P* < 0.001). View this table: [3](http://www.cancerbiomed.org/content/15/1/79/T3) 3 Risk factors of POPF ## Discussion POPF is one of the most challenging complications that are closely related to perioperative death in PD. Even in centers with high volume of pancreatic surgical cases, absolute safety is difficult to achieve. To reduce the occurrence of POPF, many domestic and foreign experts have performed numerous anastomotic and gastrointestinal reconstruction techniques18–20. In recent years, BA, which uses the jejunum as a buffer pad to prevent pancreatic laceration when knotting the sutures, has gradually stood out and has been accepted increasingly by more medical centers13. To further simplify the rigmarole of BA, Oda et al.16 tightened U-sutures after duct-to-mucosa anastomosis without knotting them and then took two needles, respectively passing them through the seromuscular antimesenteric edge of the jejunum and bringing the jejunum to cover the front of the pancreatic cut edge to finish knotting, which was defined as the one-step Blumgart method. Fujii et al,5 on the basis of the method of Oda et al,16 attempted to further reduce the U-sutures to 1 to 3 sutures, making it a safe and simple method. BA has been applied in PD since 2010 in our department. We noticed that during BA, duct-to-mucosa anastomosis was quite difficult to successfully perform in a relatively narrow space, especially when confronting a relatively small pancreatic duct. More seriously, the tightening of the suture may cause tearing of the fragile pancreatic duct, which increases the possibility of POPF. Lastly, a discontinuous pinhole of the MPD may become a potential outflow channel that increases the risk of pancreatic leakage when the pancreatic duct pressure increased. On the basis of the above-mentioned considerations, we modified the original method of duct-to-mucosa anastomosis. The advantages of the m-BA are mainly as follows: (1) we first freed the main pancreatic duct and then placed the supporting tube in to support and fully secure the MPD, which had adequate operation space; (2) the m-BA simplified the process of duct-to-mucosa anastomosis and shortened the time while also avoiding tearing of the MPD to minimize a potential POPF; (3) owing to a certain free length of the MPD into the jejunum, the supporting tube will flow directly into the jejunum in spite of a small amount of pancreatic leakage. This study was conducted to compare the m-BA with the c-BA for the first time . We analyzed and compared operation time, the incidence rate of clinically relevant POPF, and the POHS of the two groups. For the operation time, the mean time in the m-BA group was shorter than that in the c-BA group; however, the smaller time gap between the two groups was masked by the lengthy operation procedure. The incidence of clinical relevant POPF was similar between the two groups (12% *vs* 10.3%), which was consistent with previous reports21, 22. There were no significant differences in POHS duration and other complications of the two groups. In summary, the m-BA, as a convenient method for duct-to-mucosa anastomosis, did not increase the risk of pancreatic leakage and related complications. In addition, we analyzed the factors that influenced the incidence of POPF. In the univariate analysis, BMI, and MPD diameter were associated with POPF. Furthermore, the multivariate analysis revealed that only BMI was a significant factor. However, the influences of preoperative biliary drainage, pancreatic texture, anastomosis method (m-BA), operation time, intraoperative blood loss, perioperative blood transfusion, and pathological diagnosis of POPF were not significant. The correlation between BMI and POPF is still controversial. Del Chiaro et al.23 mentioned that obesity increased not only the risk of POPF but also the difficulty of operation and blood loss, but some literatures considered that no necessary correlation existed between BMI and POPF24, 25. Our study shows that BMI was associated with POPF both in the univariate anal multivariate analyses. Moreover, our study also found a significant correlation between pancreatic duct diameter and POPF in the univariate analysis, while that in the multivariate analysis was not significant. This may be related to the routine use of a supporting tube in MPD26. In conclusion, patient characteristics play an important role in POPF. The m-BA has no distinct advantage over c-BA in reducing the rate of pancreatic fistula. Many factors affect pancreatic fistula, one of which is anastomotic mode. In addition, c-BA has significantly reduced the incidence of pancreatic fistula12–14, which is difficult to surpass. Patient characteristics also play an important role in POPF. The m-BA is equal to the c-BA in terms of the incidence rate of pancreatic fistula, but it is simple, reliable, and suitable for any type of pancreatic fistula. Moreover, it requires a short learning period and has been applied to robotic pancreaticoduodenectomy safely and feasibly. Compared with the multicentral randomized controlled study, the evidence from our prospective (to some extent) but not randomized study might not be adequately sufficient. However, the safety and effectiveness of the m-BA is apparent and irreplaceable. Our study has limitations that need further improvement, including the small number of study cases. A single-center randomized controlled study is probably best to further confirm our conclusion. As we mentioned earlier, the m-BA using firm ligation of the supporting tube and MPD to replace the pancreatic duct-to-mucosa anastomosis is a simple, safe, and reliable operation method without sacrifice of surgical quality. In conclusion, the m-BA has a relatively high clinical value to reduce the duct-to-mucosa anastomosis time with no increased risk of POPF. ## Footnotes * **Conflict of interest statement** No potential conflicts of interest are disclosed. * Received October 27, 2017. * Accepted December 20, 2017. * Copyright: © 2018, Cancer Biology & Medicine [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) This is an open access article distributed under the terms of the [Creative Commons Attribution License (CC BY) 4.0](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. ## References 1. 1. Aranha GV, Hodul PJ, Creech S, Jacobs W. Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy. J Am Coll Surg. 2003; 197: 223–32. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/S1072-7515(03)00331-4&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=12892800&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000184432100007&link_type=ISI) 2. 2. Kleespies A, Rentsch M, Seeliger H, Albertsmeier M, Jauch K W, Bruns C J. Blumgart anastomosis for pancreaticojejunostomy minimizes severe complications after pancreatic head resection. Br J Surg. 2009; 96: 741–50. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/bjs.6634&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=19526614&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000267578300008&link_type=ISI) 3. 3. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006; 244: 931–7. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1097/01.sla.0000246856.03918.9a&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=17122618&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000242474700012&link_type=ISI) 4. 4. Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg. 2007; 204: 356–64. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/j.jamcollsurg.2006.11.017&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=17324768&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 5. 5. Fujii T, Sugimoto H, Yamada S, Kanda M, Suenaga M, Takami H, et al. Modified blumgart anastomosis for pancreaticojejunostomy: technical improvement in matched historical control study. J Gastrointest Surg. 2014; 18: 1108–15. 6. 6. Yu L, Huang Q, Xie F, Lin X, Liu C. Risk factors of postoperative complications of pancreatoduodenectomy. Hepatogastroenterology. 2014; 61: 2091–5. 7. 7. Muscari F, Suc B, Kirzin S, Hay JM, Fourtanier G, Fingerhut A, et al. Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: multivariate analysis in 300 patients. Surgery. 2006; 139: 591–8. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/j.surg.2005.08.012&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=16701090&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000237878600002&link_type=ISI) 8. 8. House MG, Fong Y, Arnaoutakis DJ, Sharma R, Winston CB, Protic M, et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2008; 12: 270–8. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1007/s11605-007-0421-7&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=18060467&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000252563700014&link_type=ISI) 9. 9. Peng SY, Wang JW, Lau WY, Cai XJ, Mou YP, Liu YB, et al. Conventional versus binding pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg. 2007; 245: 692–8. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1097/01.sla.0000255588.50964.5d&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=17457161&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000246036700009&link_type=ISI) 10. 10. Hines OJ, Reber HA. Technique of pancreaticojejunostomy reconstruction after pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg. 2006; 13: 185–9. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=16708292&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 11. 11. Berger AC, Howard TJ, Kennedy EP, Sauter PK, Bower-Cherry M, Dutkevitch S, et al. Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg. 2009; 208: 738–47. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/j.jamcollsurg.2008.12.031&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=19476827&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000265801500018&link_type=ISI) 12. 12. Lee JY, Kim EY, Lee JS, Lee SH, Na GH, Hong TH, et al. A novel pancreaticogastrostomy method using only two transpancreatic sutures: early postoperative surgical results compared with conventional pancreaticojejunostomy. Ann Surg Treat Res. 2015; 88: 299–305. 13. 13. Grobmyer SR, Kooby D, Blumgart LH, Hochwald SN. Novel pancreaticojejunostomy with a low rate of anastomotic failure-related complications. J Am Coll Surg. 2010; 210: 54–9. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/j.jamcollsurg.2009.09.020&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=20123332&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000279279800009&link_type=ISI) 14. 14. Mishra PK, Saluja SS, Gupta M, Rajalingam R, Pattnaik P. Blumgart’s technique of pancreaticojejunostomy: an appraisal. Dig Surg. 2011; 28: 281–7. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=21811074&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 15. 15. Kim DJ, Paik KY, Kim W, Kim EK. The effect of modified pancreaticojejunostomy for reducing the pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2014; 61: 1421–5. 16. 16. Oda T, Hashimoto S, Miyamoto R, Shimomura O, Fukunaga K, Kohno K et al, et al. The tight adaptation at pancreatic anastomosis without parenchymal laceration: an institutional experience in introducing and modifying the new procedure. World J Surg. 2015; 39: 2014–22. 17. 17. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161: 584–91. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/j.surg.2016.11.014&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 18. 18. Yang YL, Xu XP, Wu GQ, Yue SQ, Dou KF. Prevention of pancreatic leakage after pancreaticoduodenectomy by modified Child pancreaticojejunostomy. Hepatobiliary Pancreat Dis Int. 2008; 7: 426–9. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=18693181&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 19. 19. Chen XP, Huang ZY, Lau JWY, Zhang BX, Zhang ZW, Chen YF, et al. Chen's U-suture technique for end-to-end invaginated pancreaticojejunostomy following pancreaticoduodenectomy. Ann Surg Oncol. 2014; 21: 4336–41. 20. 20. Chen YJ, Zhu XF, Huang JJ, Zhu YS. End-to-side penetrating-suture pancreaticojejunostomy: a novel anastomosis technique. J Am Coll Surg. 2015; 221: e81–6. 21. 21. Chen Z, Song X, Yang D, Li Y, Xu K, He Y. Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized control trials. Eur J Surg Oncol. 2014; 40: 1177–85. 22. 22. Liu QY, Zhang WZ, Xia HT, Leng JJ, Wan T, Liang B, et al. Analysis of risk factors for postoperative pancreatic fistula following pancreaticoduodenectomy. World J Gastroenterol. 2014; 20: 17491–7. 23. 23. Del Chiaro M, Rangelova E, Ansorge C, Blomberg J, Segersvärd R. Impact of body mass index for patients undergoing pancreaticoduodenectomy. World J Gastrointest Pathophysiol. 2013; 4: 37–42. 24. 24. Zhao YP, Zhan HX, Cong L, Zhang TP, Liao Q, Dai MH, et al. Risk factors for postoperative pancreatic fistula in patients with insulinomas: analysis of 292 consecutive cases. Hepatobiliary Pancreat Dis Int. 2012; 11: 102–6. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=22251477&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 25. 25. Fu SJ, Shen SL, Li SQ, Hu WJ, Hua YP, Kuang M, et al. Risk factors and outcomes of postoperative pancreatic fistula after pancreatico-duodenectomy: an audit of 532 consecutive cases. BMC Surg. 2015; 15: 34. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=25887526&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom) 26. 26. Kimura W. Pancreaticojejunal anastomosis, using a stent tube, in pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg. 2009; 16: 305–9. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1007/s00534-009-0072-z&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=19350197&link_type=MED&atom=%2Fcbm%2F15%2F1%2F79.atom)